Abstract
Glioblastoma (glioblastoma multiforme; GBM; WHO Grade IV) accounts for the majority of primary malignant brain tumors in adults. Amplification and mutation of the epidermal growth factor receptor (EGFR) gene represent signature genetic abnormalities encountered in GBM. A range of potential therapies that target EGFR or its mutant constitutively active form, ΔEGFR, including tyrosine kinase inhibitors (TKIs), monoclonal antibodies, vaccines, and RNA-based agents, are currently in development or in clinical trials for the treatment of GBM. Data from experimental studies evaluating these therapies have been very promising; however, their efficacy in the clinic has so far been limited by both upfront and acquired drug resistance. This review discusses the current status of anti-EGFR agents and the recurrent problem of resistance to these agents that strongly indicates that a multiple target approach will provide a more favorable future for these types of targeted therapies in GBM.
Keywords: Epidermal growth factor receptor, EGFR-targeted therapy, Glioblastoma, therapeutic resistance, carmustine, cluster of differentiation, adenosine triphosphate, cyclodextrin-modified dendritic polyamine complexes, Glioblastoma multiforme, janus kinase, non small cell lung carcinoma, mammalian target of rapamycin, receptor tyrosine kinases, temozolomide, urokinase plasminogen activator receptor
Current Cancer Drug Targets
Title: Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Volume: 12 Issue: 3
Author(s): T. E. Taylor, F. B. Furnari and W. K. Cavenee
Affiliation:
Keywords: Epidermal growth factor receptor, EGFR-targeted therapy, Glioblastoma, therapeutic resistance, carmustine, cluster of differentiation, adenosine triphosphate, cyclodextrin-modified dendritic polyamine complexes, Glioblastoma multiforme, janus kinase, non small cell lung carcinoma, mammalian target of rapamycin, receptor tyrosine kinases, temozolomide, urokinase plasminogen activator receptor
Abstract: Glioblastoma (glioblastoma multiforme; GBM; WHO Grade IV) accounts for the majority of primary malignant brain tumors in adults. Amplification and mutation of the epidermal growth factor receptor (EGFR) gene represent signature genetic abnormalities encountered in GBM. A range of potential therapies that target EGFR or its mutant constitutively active form, ΔEGFR, including tyrosine kinase inhibitors (TKIs), monoclonal antibodies, vaccines, and RNA-based agents, are currently in development or in clinical trials for the treatment of GBM. Data from experimental studies evaluating these therapies have been very promising; however, their efficacy in the clinic has so far been limited by both upfront and acquired drug resistance. This review discusses the current status of anti-EGFR agents and the recurrent problem of resistance to these agents that strongly indicates that a multiple target approach will provide a more favorable future for these types of targeted therapies in GBM.
Export Options
About this article
Cite this article as:
E. Taylor T., B. Furnari F. and K. Cavenee W., Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance, Current Cancer Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/156800912799277557
DOI https://dx.doi.org/10.2174/156800912799277557 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Erythrocyte-cancer Hybrid Membrane-camouflaged Mesoporous Silica
Nanoparticles Loaded with Gboxin for Glioma-targeting Therapy
Current Pharmaceutical Biotechnology In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Radiation Therapy of Cancer Cells: A Step towards an Experimental and Systems Biology Framework
Current Radiopharmaceuticals Targeting Glioblastoma Stem Cells: Cell Surface Markers
Current Medicinal Chemistry Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry Finding Recurrent Copy Number Alteration Regions: A Review of Methods
Current Bioinformatics Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review
Current Medicinal Chemistry Neural Stem Cells - A Promising Potential Therapy for Brain Tumors
Current Stem Cell Research & Therapy Hypoxia-Inducible Factor-1 as Regulator of Angiogenesis in Rheumatoid Arthritis - Therapeutic Implications
Current Medicinal Chemistry The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design An Update of the Classical and Novel Methods Used for Measuring Fast Neurotransmitters During Normal and Brain Altered Function
Current Neuropharmacology Melanoma Differentiation Associated Gene-7 (mda-7)/ Interleukin-24 (IL-24), mda-7/IL-24: Current Perspectives on a Unique Member of the IL-10 Family of Cytokines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neuropilin Signalling in Vascular Development and Pathology
Current Angiogenesis (Discontinued) Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Emerging Therapeutic Targets and Agents for Glioblastoma Therapy – Part I (Guest Editor: Hui-Wen Lo)]
Anti-Cancer Agents in Medicinal Chemistry Hemisynthesis of Selected Embelin Analogs and Investigation of their Proapoptotic Activity Against Cancer Cells
Medicinal Chemistry Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology